Hims & Hers Health Stock Climbs Following Q4 Earnings Beat, Revenue Beat, Guidance Above Estimates

Hims & Hers Health, Inc. HIMS reported better-than-expected fourth-quarter financial results after the bell Monday. Here's a look at the highlights.

The Details:

Hims & Hers Health reported quarterly earnings of 1 cent per share which beat the analyst consensus estimate of losses of 3 cents per share.

The company reported quarterly sales of $246.62 million which beat the analyst consensus estimate of $245.82 million by 0.33% and represents a 47.5% increase over sales of $167.2 million from the same period last year.

Hims & Hers said subscribers grew to 1.5 million, up 48% year-over-year in the fourth quarter.

“Our outstanding results in 2023 underscore the power of the Hims & Hers brands and superior execution across the organization,” said Andrew Dudum, CEO of Hims & Hers Health.

“We are continuing to advance our mission to make the world feel great through the power of better health, which is evident in the significant, consistent and category-leading revenue growth and market share gains we have been delivering. In 2024, we expect to eclipse $1 billion in revenue and deliver our first full year of net income profitability through a continued focus on building personalized and accessible treatments in each of our core specialties,” Dudum added.

Outlook: 

Hims & Hers Health sees first-quarter 2024 revenue in the range of $267 million to $272 million, versus the $252.548 million estimate. The company sees fiscal year 2024 revenue of between $1.17 billion and $1.20 billion, versus the $1.099 billion estimate.

Related News: Berkshire Hathaway Report, Shareholder Letter Released: What’s Going On With The Stock?

HIMS Price Action: According to Benzinga Pro, Hims & Hers shares are trading up 16.1% after-hours at $11.90 at the time of publication.

Image: Courtesy of Hims & Hers Health, Inc.